AU2018279306C1 - Compounds and compositions for inducing chondrogenesis - Google Patents

Compounds and compositions for inducing chondrogenesis Download PDF

Info

Publication number
AU2018279306C1
AU2018279306C1 AU2018279306A AU2018279306A AU2018279306C1 AU 2018279306 C1 AU2018279306 C1 AU 2018279306C1 AU 2018279306 A AU2018279306 A AU 2018279306A AU 2018279306 A AU2018279306 A AU 2018279306A AU 2018279306 C1 AU2018279306 C1 AU 2018279306C1
Authority
AU
Australia
Prior art keywords
carboxamide
compound
substituted
dichlorophenyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018279306A
Other languages
English (en)
Other versions
AU2018279306A1 (en
AU2018279306B2 (en
Inventor
Ha-Soon Choi
Jiqing Jiang
James Paul LAJINESS
Bao Nguyen
Hank Michael James Petrassi
Zhicheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2018279306A1 publication Critical patent/AU2018279306A1/en
Application granted granted Critical
Publication of AU2018279306B2 publication Critical patent/AU2018279306B2/en
Publication of AU2018279306C1 publication Critical patent/AU2018279306C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018279306A 2017-06-09 2018-06-07 Compounds and compositions for inducing chondrogenesis Active AU2018279306C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09
US62/517,394 2017-06-09
PCT/IB2018/054123 WO2018225009A1 (en) 2017-06-09 2018-06-07 Compounds and compositions for inducing chondrogenesis

Publications (3)

Publication Number Publication Date
AU2018279306A1 AU2018279306A1 (en) 2019-12-05
AU2018279306B2 AU2018279306B2 (en) 2020-07-09
AU2018279306C1 true AU2018279306C1 (en) 2021-01-14

Family

ID=62837959

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018279306A Active AU2018279306C1 (en) 2017-06-09 2018-06-07 Compounds and compositions for inducing chondrogenesis

Country Status (37)

Country Link
US (3) US11091499B2 (enExample)
EP (3) EP3634967A1 (enExample)
JP (2) JP7229945B2 (enExample)
KR (1) KR102656524B1 (enExample)
CN (1) CN110719913B (enExample)
AR (1) AR113227A1 (enExample)
AU (1) AU2018279306C1 (enExample)
BR (1) BR112019025866A2 (enExample)
CL (1) CL2019003564A1 (enExample)
CO (1) CO2019013706A2 (enExample)
CR (1) CR20190551A (enExample)
CU (1) CU24577B1 (enExample)
DK (1) DK3915994T3 (enExample)
DO (1) DOP2019000305A (enExample)
EA (1) EA201992858A1 (enExample)
EC (1) ECSP19086712A (enExample)
ES (1) ES2971319T3 (enExample)
FI (1) FI3915994T3 (enExample)
HR (1) HRP20240155T1 (enExample)
HU (1) HUE065194T2 (enExample)
IL (2) IL300755A (enExample)
JO (1) JOP20190282B1 (enExample)
LT (1) LT3915994T (enExample)
MA (2) MA50547A (enExample)
MX (1) MX389169B (enExample)
MY (1) MY198288A (enExample)
PE (1) PE20200403A1 (enExample)
PH (1) PH12019502764A1 (enExample)
PL (1) PL3915994T3 (enExample)
PT (1) PT3915994T (enExample)
RS (1) RS65161B1 (enExample)
SA (1) SA519410729B1 (enExample)
SI (1) SI3915994T1 (enExample)
TW (1) TWI782036B (enExample)
UY (1) UY37759A (enExample)
WO (1) WO2018225009A1 (enExample)
ZA (1) ZA201907358B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11753416B2 (en) 2017-06-09 2023-09-12 Novartis Ag Compounds and compositions for inducing chondrogenesis

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2963508T3 (es) * 2018-12-06 2024-03-27 Novartis Ag Derivados de 5-hidroxi-7-oxabiciclo[2.2.1]heptano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
WO2020115684A1 (en) * 2018-12-06 2020-06-11 Novartis Ag 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015175487A1 (en) * 2014-05-13 2015-11-19 Novartis Ag Compounds and compositions for inducing chondrogenesis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6407250B1 (en) * 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物，其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7595327B2 (en) * 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
US9233106B2 (en) 2006-07-12 2016-01-12 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2010114997A1 (en) 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
PE20160507A1 (es) 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
CN101628951B (zh) 2009-08-12 2011-06-22 中国石油天然气股份有限公司 烯烃聚合用固体催化组分及其催化剂
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (en) 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
EP2968330B1 (en) * 2013-03-15 2021-09-29 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
UY37759A (es) 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015175487A1 (en) * 2014-05-13 2015-11-19 Novartis Ag Compounds and compositions for inducing chondrogenesis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11753416B2 (en) 2017-06-09 2023-09-12 Novartis Ag Compounds and compositions for inducing chondrogenesis
US12209096B2 (en) 2017-06-09 2025-01-28 Novartis Ag Compounds and compositions for inducing chondrogenesis

Also Published As

Publication number Publication date
EP4299123A2 (en) 2024-01-03
EP4299123A3 (en) 2024-04-03
TW201902900A (zh) 2019-01-16
MX389169B (es) 2025-03-20
JOP20190282B1 (ar) 2024-04-18
IL300755A (en) 2023-04-01
CN110719913A (zh) 2020-01-21
JP7432778B2 (ja) 2024-02-16
NZ759434A (en) 2024-01-26
CO2019013706A2 (es) 2020-04-01
RU2019144107A3 (enExample) 2021-07-30
PH12019502764A1 (en) 2020-07-13
AU2018279306A1 (en) 2019-12-05
US20210079010A1 (en) 2021-03-18
HRP20240155T1 (hr) 2024-04-12
CN110719913B (zh) 2022-10-28
PE20200403A1 (es) 2020-02-26
CU24577B1 (es) 2022-02-04
EP3634967A1 (en) 2020-04-15
MA50547A (fr) 2020-09-16
BR112019025866A2 (pt) 2020-07-14
CR20190551A (es) 2020-01-28
KR102656524B1 (ko) 2024-04-12
FI3915994T3 (fi) 2024-02-14
MA57022B1 (fr) 2024-02-29
IL271154B2 (en) 2023-07-01
JP2023062064A (ja) 2023-05-02
SA519410729B1 (ar) 2022-07-03
PT3915994T (pt) 2024-02-15
JP7229945B2 (ja) 2023-02-28
JOP20190282A1 (ar) 2019-12-05
DOP2019000305A (es) 2019-01-15
TWI782036B (zh) 2022-11-01
ES2971319T3 (es) 2024-06-04
US20230365580A1 (en) 2023-11-16
IL271154B1 (en) 2023-03-01
WO2018225009A1 (en) 2018-12-13
PL3915994T3 (pl) 2024-05-20
EP3915994A1 (en) 2021-12-01
KR20200013046A (ko) 2020-02-05
US20210347784A1 (en) 2021-11-11
CU20190098A7 (es) 2020-10-20
US12209096B2 (en) 2025-01-28
EP3915994B9 (en) 2024-02-28
MX2019014757A (es) 2020-02-12
AU2018279306B2 (en) 2020-07-09
AR113227A1 (es) 2020-02-19
DK3915994T3 (da) 2024-02-19
MY198288A (en) 2023-08-21
CL2019003564A1 (es) 2020-06-19
ZA201907358B (en) 2022-04-28
US11753416B2 (en) 2023-09-12
UY37759A (es) 2019-01-31
IL271154A (en) 2020-01-30
EA201992858A1 (ru) 2020-04-02
EP3915994B1 (en) 2023-11-22
CA3063985A1 (en) 2018-12-13
RU2019144107A (ru) 2021-07-09
RS65161B1 (sr) 2024-02-29
JP2020522550A (ja) 2020-07-30
HUE065194T2 (hu) 2024-05-28
SI3915994T1 (sl) 2024-03-29
LT3915994T (lt) 2024-02-26
US11091499B2 (en) 2021-08-17
ECSP19086712A (es) 2019-12-27

Similar Documents

Publication Publication Date Title
EP3218376B1 (en) Bromodomain inhibitors and uses thereof
US12209096B2 (en) Compounds and compositions for inducing chondrogenesis
TWI828712B (zh) 作為ｔｒｋ抑制劑的雜環化合物
EA036122B1 (ru) Ингибитор jak
CA3063934A1 (en) Kinase inhibitors and uses thereof
EP3891154B1 (en) 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
HK40096806A (en) Compounds and compositions for inducing chondrogenesis
RU2773943C2 (ru) Соединения и композиции для индуцирования хондрогенеза
HK40055222A (en) Compounds and compositions for inducing chondrogenesis
HK40055222B (en) Compounds and compositions for inducing chondrogenesis
EA040531B1 (ru) Соединения и композиции для индукцирования хондрогенеза
WO2017030171A1 (ja) テトラヒドロオキセピノピリジン化合物

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 SEP 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 28 SEP 2020

FGA Letters patent sealed or granted (standard patent)